Clinical Summary: Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Many adults with major depressive disorder remain symptomatic despite an adequate antidepressant trial, and augmentation options are often limited by motor, metabolic, prolactin, or weight-related adverse effects. This trial addresses a common treatment impasse: whether adjunctive lumateperone 42 mg can improve depressive symptoms in patients with inadequate antidepressant response without adding major safety burden.
Key Findings
- Adjunctive lumateperone + ADT significantly improved depressive symptoms versus placebo + ADT on the primary outcome, reducing MADRS Total score from baseline to day 43 with least squares mean difference [LSMD] vs placebo = −4.9; 95% CI, −6.38 to −3.44; effect size [ES] = −0.61; P <.0001.
- Disease severity also improved on the key secondary outcome, with CGI-S score reduction from baseline to day 43 of LSMD = −0.7; 95% CI, −0.85 to −0.48; ES = −0.67; P <.0001 versus placebo + ADT.
- Among patients meeting DSM-5 anxious distress criteria at baseline, nearly half of the sample, lumateperone + ADT significantly improved MADRS Total score and CGI-S score; anxious distress was present in placebo + ADT, n=99 [40.7%] and lumateperone + ADT, n=110 [45.6%].
- Treatment-emergent adverse events occurred in 58.1% with lumateperone + ADT versus 46.5% with placebo + ADT, but most TEAEs (>98%) were mild or moderate severity, and discontinuation due to a TEAE occurred in 13 patients receiving lumateperone + ADT and 2 patients receiving placebo + ADT.
- EPS-related TEAEs were uncommon but more frequent with lumateperone + ADT than placebo + ADT, occurring in 15 patients (6.2%) versus 7 patients (2.9%); tremor was observed in 12 patients in the lumateperone + ADT group and in 1 patient in the placebo + ADT group, with mean (SD) duration 14.6 days (±10.65 days).
For adults with MDD and inadequate response to 1 or 2 antidepressants, adjunctive lumateperone 42 mg produced clinically meaningful improvement in depressive symptoms and global severity over 6 weeks. The tradeoff was a higher TEAE rate, but weight, cardiometabolic measures, prolactin, and serious motor liability remained low and generally similar to placebo.
Practice Implications
- Consider lumateperone 42 mg augmentation when a patient has inadequate response after 1 or 2 adequate ADT trials and tolerability concerns make other adjunctive antipsychotics less appealing.
- Set expectations for early follow-up, since the discussion reports clinically meaningful, significant improvements by day 8 that persisted throughout the study.
- Monitor for early tremor, fatigue, dizziness, sedation, and dry mouth; most tremor cases began during the first 2 weeks, were mild or moderate, and only 1 patient discontinued due to tremor.
- If metabolic or prolactin burden is a key concern, this study supports lumateperone as an option with no notable changes at the end of treatment in weight, body mass index, or waist circumference, and with cardiometabolic parameters and prolactin generally similar between groups.
